Loading…
Cingulate Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -99.3% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $4.34 | $4.93 | $91.80 | $240.00 | $662.40 | |
| P/B | 2.7x | 20.1x | 2.5x | — | 2.9x | 1.5x |
| EPS | -$4.44 | -$10.86 | -$311.99 | -$352.20 | -$669.60 | |
| ROE | -338.72% | -894.81% | -222.11% | — | -455.34% | -99.36% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| GANXGain Therapeutics, Inc. | $1.77 | — | 6.8x | — | -268.30% | $77.25M |
| APLMApollomics Inc. | $26.60 | — | — | — | -1305.37% | $77.04M |
| TELOTelomir Pharmaceuticals, Inc. | $1.14 | — | 7.9x | — | -213.10% | $78.4M |
| CVRXCVRx, Inc. | $2.95 |
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Company description provided by Yahoo Finance.
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 3.9x |
| — |
| -133.44% |
| $78.59M |
| OSTXOS Therapies Inc | $1.64 | — | — | — | — | $76.21M |
| RPIDRapid Micro Biosystems Inc | $1.57 | — | 4.4x | — | -141.65% | $78.75M |